Compare PERF & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PERF | CBIO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 198.9M |
| IPO Year | N/A | N/A |
| Metric | PERF | CBIO |
|---|---|---|
| Price | $1.73 | $10.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | ★ 103.4K | 99.2K |
| Earning Date | 02-25-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.89 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,900,999.00 | N/A |
| Revenue This Year | $17.03 | N/A |
| Revenue Next Year | $14.17 | N/A |
| P/E Ratio | $31.30 | ★ N/A |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $1.51 | $9.81 |
| 52 Week High | $2.87 | $21.40 |
| Indicator | PERF | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 32.80 |
| Support Level | $1.70 | $10.86 |
| Resistance Level | $1.82 | $11.68 |
| Average True Range (ATR) | 0.07 | 0.72 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 25.71 | 7.63 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.